| Mr David Lynn Blauvelt, PA-C | |
|
2714 2nd Ave Ste A, Kearney, NE 68847-4437 | |
| (308) 236-7016 | |
| (308) 236-7027 |
| Full Name | Mr David Lynn Blauvelt |
|---|---|
| Gender | Male |
| Speciality | Physician Assistant |
| Experience | 27 Years |
| Location | 2714 2nd Ave Ste A, Kearney, Nebraska |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1447367230 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 363AM0700X | Physician Assistant - Medical | 763 (Nebraska) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Chi Health Good Samaritan | Kearney, NE | Hospital |
| The Nebraska Medical Center | Omaha, NE | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| First Care Medical Pc | 6305901513 | 6 |
| Quality Urgent Care | 5799823423 | 5 |
News Archive
Affymax, Inc. and Takeda Pharmaceutical Company Limited , today announced that following pre-New Drug Application (NDA) discussions with the U.S. Food and Drug Administration (FDA), the companies will move forward with their regulatory strategy for the investigational drug, peginesatide, for the treatment of anemia in chronic renal failure (CRF) patients on dialysis in the United States.
The American Parkinson Disease Association (APDA) National Young Onset Center and the National Parkinson Foundation (NPF) Young Onset Parkinson Network are co-sponsoring a series of conferences for those living with young-onset Parkinson's disease and their caregivers. The first conference will be held in Dallas, Texas on October 23-24.
Artificial intelligence technology developed by the RIKEN Center for Advanced Intelligence Project in Japan has successfully found features in pathology images from human cancer patients, without annotation, that could be understood by human doctors.
Wounded Warrior Project (WWP) will move into a new office in Los Angeles today to start 2016, providing the nonprofit veteran's service organization with its most prominent presence in the greater Los Angeles area.
Following a priority review, Health Canada has approved Lucentis (ranibizumab) as a treatment for vision loss resulting from retinal vein occlusion (RVO). This makes Lucentis the first approved treatment of its class in Canada for this debilitating condition. Patients will now have access to a treatment that is proven to be effective and has an established safety profile.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Mr David Lynn Blauvelt, PA-C 2715 Evergreen Rd, Kearney, NE 68845-0357 Ph: (308) 293-3848 | Mr David Lynn Blauvelt, PA-C 2714 2nd Ave Ste A, Kearney, NE 68847-4437 Ph: (308) 236-7016 |
News Archive
Affymax, Inc. and Takeda Pharmaceutical Company Limited , today announced that following pre-New Drug Application (NDA) discussions with the U.S. Food and Drug Administration (FDA), the companies will move forward with their regulatory strategy for the investigational drug, peginesatide, for the treatment of anemia in chronic renal failure (CRF) patients on dialysis in the United States.
The American Parkinson Disease Association (APDA) National Young Onset Center and the National Parkinson Foundation (NPF) Young Onset Parkinson Network are co-sponsoring a series of conferences for those living with young-onset Parkinson's disease and their caregivers. The first conference will be held in Dallas, Texas on October 23-24.
Artificial intelligence technology developed by the RIKEN Center for Advanced Intelligence Project in Japan has successfully found features in pathology images from human cancer patients, without annotation, that could be understood by human doctors.
Wounded Warrior Project (WWP) will move into a new office in Los Angeles today to start 2016, providing the nonprofit veteran's service organization with its most prominent presence in the greater Los Angeles area.
Following a priority review, Health Canada has approved Lucentis (ranibizumab) as a treatment for vision loss resulting from retinal vein occlusion (RVO). This makes Lucentis the first approved treatment of its class in Canada for this debilitating condition. Patients will now have access to a treatment that is proven to be effective and has an established safety profile.
› Verified 2 days ago
Bruce Lynn Kohtz, PA-C Physician Assistant Medicare: Accepting Medicare Assignments Practice Location: 2810 W 35th St, Kearney, NE 68845 Phone: 308-865-2570 Fax: 308-865-2508 | |
Jacob M Andreasen, PA-C Physician Assistant Medicare: Accepting Medicare Assignments Practice Location: 5205 2nd Ave, Kearney, NE 68847 Phone: 308-237-9696 | |
Agrini Boken, Physician Assistant Medicare: Not Enrolled in Medicare Practice Location: 3 Hillcrest Dr, Kearney, NE 68845 Phone: 402-969-0474 | |
Amy Martinez, P.A. Physician Assistant Medicare: Accepting Medicare Assignments Practice Location: 3219 Central Ave, Kearney, NE 68847 Phone: 308-865-2808 | |
Rebecca Garry, Physician Assistant Medicare: Accepting Medicare Assignments Practice Location: 3219 Central Ave Ste 102a, Kearney, NE 68847 Phone: 308-865-2600 | |
Kelly Marie Stevenson, PA-C Physician Assistant Medicare: Accepting Medicare Assignments Practice Location: 804 22nd Ave, Kearney, NE 68845 Phone: 308-455-3600 Fax: 308-455-3950 | |
Nicholas Kolar, PA-C Physician Assistant Medicare: Accepting Medicare Assignments Practice Location: 3219 Central Ave Ste 102a, Kearney, NE 68847 Phone: 308-865-2600 |